Related references
Note: Only part of the references are listed.FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
Shaily Arora et al.
ONCOLOGIST (2021)
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2020)
Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis
Aaron Dane et al.
PHARMACEUTICAL STATISTICS (2019)
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials
Mohamed Alosh et al.
STATISTICS IN MEDICINE (2017)
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen
Christy L. Osgood et al.
CLINICAL CANCER RESEARCH (2017)
General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials
Alex Dmitrienko et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2016)
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
Dickran Kazandjian et al.
ONCOLOGIST (2016)
Bayesian models for subgroup analysis in clinical trials
Hayley E. Jones et al.
CLINICAL TRIALS (2011)